New 'Living Drug' trial targets Tough-to-Treat blood cancers
NCT ID NCT07365059
Summary
This early-stage study is testing the safety and effectiveness of a new type of CAR-T cell therapy called GPRC5D CAR-T. It is for adults and teens (14-75) with advanced plasma cell cancers, like multiple myeloma, that have come back or stopped responding to other treatments, including stem cell transplants. The main goals are to see if the treatment is safe, how well it works, and how long the modified cells last in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL DYSCRASIAS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.